Regulatory overview of biosimilars in Europe
Journal Title: International Journal of Drug Regulatory Affairs - Year 2018, Vol 6, Issue 3
Abstract
A biosimilar is a biological medicine similar, but not identical, to an already registered reference bio therapeutic product in terms of quality, safety, and efficacy. These drugs are also called as biosimilar products„, follow-on protein products‟ and subsequent-entry biologics„. The EU has pioneered the regulation of biosimilar medicines by establishing a solid framework for their approval and by shaping biosimilar development globally. Since the EU approved the first biosimilar in 2006, healthcare professionals have gained increasing experience with their use. Today, biosimilars are an integral part of the effective biological therapies available in the EU, supported by adequate safeguards protecting patient safety. In Europe, in 2001, legislation concerning biosimilar was codified as Directive 2001/83/EC to create a new marketing authorization procedure for similar biological medicinal products and also Committee for Medicinal Products for Human Use (CHMP) of the EMA is concern with these biosimilar products. The aim of biosimilars development is to demonstrate bio similarity - high similarity in terms of structure, biological activity and efficacy, safety and immunogenicity profile. Safety of biosimilars is monitored through pharmacovigilance activities, in the same way as for any other medicine. Biosimilars can offer advantages to EU healthcare systems, as it is expected to improve patients‟ access to safe and effective biological medicines with proven quality.
Authors and Affiliations
Shailaja Pashikanti, Jyothi Sri Durga V, Sowmya A. N. V. L
Keywords
Related Articles
- EP ID EP426949
- DOI 10.22270/ijdra.v6i3.270
- Views 112
- Downloads 0
MARKETING AUTHORIZATION APPLICATION (MAA) FOR EUROPE MARKET
This article states requirement of Marketing Authorization Application to get registration of Drug Product to EEA. The procedures for application of marketing authorization are: Centralised procedure, National procedure,...
Simultaneous estimation of xanthine alkaloids (Theophylline, Theobromine and Caffeine) by High-Performance Liquid Chromatography
Methylxanthines are mainly a group of phytochemicals which are derived from purine base xanthine. These xanthines are obtained from plant as a result of secondary metabolism. There are various physiological actions that...
ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF DILTIAZEM HYDROCHLORIDE IN BULK AND PHARMACEUTICAL DOSAGE FORM BY RP- HPLC
A simple, specific, precise and accurate Reverse Phase High Performance Liquid Chromatography (RP-HPLC) method was developed and validated for the estimation of Diltiazem Hydrochloride in bulk and pharmaceutical dosage f...
A COMPARISON OF NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES ACT WITH DRUGS AND COSMETICS ACT: SALIENT DIFFERENCES
This article assesses the comparison of Narcotic Drugs and Psychotropic Substances Act (NDPS Act) with the Drug and Cosmetic Act (D & C Act) and also point out the salient features of NDPS Act. Drugs and Cosmetics Act, 1...
COMPARATIVE STUDY FOR GENERIC DRUG APPROVAL PROCESS AND THEIR REGISTRATION AS PER CTD IN EUROPE, USA AND BRAZIL
This aims to compare the generic drug approval and registration process in the regulatory market of Europe, USA and Brazil. Based on the information collected from various sources such as regulatory sites, Government web...